Literature DB >> 33655079

Impact of baseline cases of cough and fever on UK COVID-19 diagnostic testing rates: estimates from the Bug Watch community cohort study.

Max T Eyre1,2, Rachel Burns3, Victoria Kirkby3, Catherine Smith4, Spiros Denaxas4,5,6,7,8, Vincent Nguyen3,9, Andrew Hayward9, Laura Shallcross4, Ellen Fragaszy4,10, Robert W Aldridge3.   

Abstract

Background: Diagnostic testing forms a major part of the UK's response to the current coronavirus disease 2019 (COVID-19) pandemic with tests offered to anyone with a continuous cough, high temperature or anosmia. Testing capacity must be sufficient during the winter respiratory season when levels of cough and fever are high due to non-COVID-19 causes. This study aims to make predictions about the contribution of baseline cough or fever to future testing demand in the UK.
Methods: In this analysis of the Bug Watch prospective community cohort study, we estimated the incidence of cough or fever in England in 2018-2019. We then estimated the COVID-19 diagnostic testing rates required in the UK for baseline cough or fever cases for the period July 2020-June 2021. This was explored for different rates of the population requesting tests and four COVID-19 second wave scenarios. Estimates were then compared to current national capacity.
Results: The baseline incidence of cough or fever in the UK is expected to rise rapidly from 154,554 (95%CI 103,083 - 231,725) cases per day in August 2020 to 250,708 (95%CI 181,095 - 347,080) in September, peaking at 444,660 (95%CI 353,084 - 559,988) in December. If 80% of baseline cough or fever cases request tests, average daily UK testing demand would exceed current capacity for five consecutive months (October 2020 to February 2021), with a peak demand of 147,240 (95%CI 73,978 - 239,502) tests per day above capacity in December 2020. Conclusions: Our results show that current national COVID-19 testing capacity is likely to be exceeded by demand due to baseline cough and fever alone. This study highlights that the UK's response to the COVID-19 pandemic must ensure that a high proportion of people with symptoms request tests, and that testing capacity is immediately scaled up to meet this high predicted demand. Copyright:
© 2020 Eyre MT et al.

Entities:  

Keywords:  COVID-19; United Kingdom; cough; diagnostic testing capacity; fever; swab test

Year:  2020        PMID: 33655079      PMCID: PMC7890379          DOI: 10.12688/wellcomeopenres.16304.1

Source DB:  PubMed          Journal:  Wellcome Open Res        ISSN: 2398-502X


  3 in total

1.  Changes to the sebum lipidome upon COVID-19 infection observed via rapid sampling from the skin.

Authors:  Matt Spick; Katherine Longman; Cecile Frampas; Holly Lewis; Catia Costa; Deborah Dunn Walters; Alex Stewart; Michael Wilde; Danni Greener; George Evetts; Drupad Trivedi; Perdita Barran; Andy Pitt; Melanie Bailey
Journal:  EClinicalMedicine       Date:  2021-03-06

2.  COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors.

Authors:  Joshua Elliott; Barbara Bodinier; Paul Elliott; Marc Chadeau-Hyam; Matthew Whitaker; Cyrille Delpierre; Roel Vermeulen; Ioanna Tzoulaki
Journal:  Eur J Epidemiol       Date:  2021-02-15       Impact factor: 8.082

3.  Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry.

Authors:  Matt Spick; Holly M Lewis; Michael J Wilde; Christopher Hopley; Jim Huggett; Melanie J Bailey
Journal:  Metabolism       Date:  2021-10-27       Impact factor: 8.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.